Cite
Kakumu S, Matsushima T, Sato S, et al. Serum HCV RNA levels during early phase of recombinant interferon alfa-2a (Roferon A) therapy for chronic hepatitis C and efficacy of short-term therapy with earlier loss of viremia. Hepatol Res. 2002;22(2):152-160doi: 10.1016/s1386-6346(01)00136-x.
Kakumu, S., Matsushima, T., Sato, S., Kobayashi, K., Kiyosawa, K., Hayashi, N., Tsuji, T., Sata, M., Origasa, H., & Iino, S. (2002). Serum HCV RNA levels during early phase of recombinant interferon alfa-2a (Roferon A) therapy for chronic hepatitis C and efficacy of short-term therapy with earlier loss of viremia. Hepatology research : the official journal of the Japan Society of Hepatology, 22(2), 152-160. https://doi.org/10.1016/s1386-6346(01)00136-x
Kakumu, Shinichi, et al. "Serum HCV RNA levels during early phase of recombinant interferon alfa-2a (Roferon A) therapy for chronic hepatitis C and efficacy of short-term therapy with earlier loss of viremia." Hepatology research : the official journal of the Japan Society of Hepatology vol. 22,2 (2002): 152-160. doi: https://doi.org/10.1016/s1386-6346(01)00136-x
Kakumu S, Matsushima T, Sato S, Kobayashi K, Kiyosawa K, Hayashi N, Tsuji T, Sata M, Origasa H, Iino S. Serum HCV RNA levels during early phase of recombinant interferon alfa-2a (Roferon A) therapy for chronic hepatitis C and efficacy of short-term therapy with earlier loss of viremia. Hepatol Res. 2002 Feb;22(2):152-160. doi: 10.1016/s1386-6346(01)00136-x. PMID: 11818255.
Copy
Download .nbib